MENU
IMTX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Immatics (IMTX) Ownership - Who owns Immatics?
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients... Show more
Profile
Industry
N/A
Address
Paul-Ehrlich-Strasse 15
Phone
+49 707153970
Employees
343
Web
https://www.immatics.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
658.8M
P/E Ratio
29.35
Total Cash
543.76M
Projected Growth
N/A
Total Debt
18.39M
Revenue
144.15M
Risk (Beta)
0.99
Dividend Yield
N/A
Total Cash/Share
4.47
Total Debt/Equity
N/A
Revenue/Share
1.51 USD as % of share price
Fundamentals
IMTX
Capitalization
659M
P/E Ratio
29.35
Risk (Beta)
0.99
Dividend Yield
N/A
Total Cash
544M
Total Cash/Share
4.47
Total Debt
18.4M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
1.51%
Revenue
144M
ROE
N/A
Book Value
537M
P/B Ratio
1.05
Cash Flow
N/A
Earnings
-0.17
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
1.22M
Current Ratio
10.28
Current Revenue Per Employee
43929.08
Dividends Per Share - Security
N/A
EBITDA
-4.49M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-3.46
Shares Held By Institutions
541M
Shares Outstanding - Current
122M
Total Liabilities
105M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-23.629
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
Paul-Ehrlich-Strasse 15
Phone
+49 707153970
Employees
343
Web
https://www.immatics.com